Guo, Robin
Luo, Jia http://orcid.org/0000-0003-3606-827X
Chang, Jason http://orcid.org/0000-0002-1705-1870
Rekhtman, Natasha
Arcila, Maria
Drilon, Alexander http://orcid.org/0000-0001-6806-9061
Article History
Accepted: 22 April 2020
First Online: 8 June 2020
Competing interests
: R.G., J.L., J.C. and N.R. declare no competing interests. M.A. has received honoraria/speaker fees from Biocartis and Invivoscribe relating to activities outside the submitted work. A.D. has received honoraria/speaker fees from Abbvie, AstraZeneca, Beigene, BergenBio, Blueprint Medicines, Exelixis, Hengrui Therapeutics, Helsinn, Ignyta/Genentech/Roche, Lilly, Loxo, Loxo/Bayer/Lilly, Medscape, MORE Health, OncLive, PeerVoice, Pfizer, Physicians Education Resources, Research to Practice, Takeda/Ariad/Millennium, Targeted Oncology, TP Therapeutics, Tyra Biosciences, Verastem and Wolters Kluwer; has served on/received fees for membership of the advisory board of Abbvie, AstraZeneca, Beigene, BergenBio, Blueprint Medicines, Exelixis, Hengrui Therapeutics, Helsinn, Ignyta/Genentech/Roche, Loxo, Loxo/Bayer/Lilly, MORE Health, Pfizer, Takeda/Ariad/Millennium, TP Therapeutics, Tyra Biosciences and Verastem; has received research funding from Exelixis, Foundation Medicine, GlaxoSmithKline, Ignyta/Roche, Pfizer, PharmaMar, Taiho and Teva; and has received non-financial support from Ignyta/Roche, Merck and Puma.